Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AKRO vs JNJ: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

JNJ Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

JNJ Overall Winner 6-Pillar Tally: AKRO 0 – 6 JNJ Matrix Metrics: AKRO 3 – 7 JNJ

As of Nov 20, 2026, Johnson & Johnson (JNJ) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKRO carries a Unified Composite Score of 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin), whereas JNJ carries 57.8/100 (HOLD) at $270.47 (23.3x Forward P/E, 26.6% operating margin).

  • Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. JNJ 57.8/100 HOLD), JNJ captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (26.6% vs. 0.0% operating margin) and revenue trajectory (+5.9% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AKRO vs JNJ
AKRO NASDAQ
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.90β · 2% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 67
RSI-14: 67.3 · SMA20: $54.36 · SMA50: $52.91
JNJ NYSE Head-to-Head Winner
Johnson & Johnson
Pharmaceutical Preparations
$270.47
+1.25% 1D
Market Cap $643.1B
TTM Revenue $99.3B
Forward P/E 23.3x
Beta / 30D Vol -0.04β · 25% Vol
Unified Composite Score
57.8 / 100 HOLD
Tech 47.0 Fund 54.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 48.1 · SMA20: $275.01 · SMA50: $267.43

6-Pillar Scorecard Institutional Category Breakdown (AKRO 0 – 6 JNJ)

Columns: Metric · AKRO · JNJ
1. Valuation Multiples JNJ
Forward P/E N/M 23.3x
Trailing P/E N/M 40.5x
PEG Ratio N/M 3.07x
EV / Revenue N/M 6.8x
2. Growth & Scale JNJ
Revenue Growth (YoY) +0.0% +5.9%
Earnings Growth (YoY) +0.0% -95.9%
TTM Revenue (USD) N/A $99.3B
Market Cap $4.5B $643.1B
3. Profitability & Quality JNJ
Gross Margin N/A 67.8%
Operating Margin 0.0% 26.6%
Net Profit Margin 0.0% 16.2%
Return on Equity (ROE) -34.5% 20.0%
4. Balance Sheet & Cash Flow JNJ
Cash Generation (TTM) N/A $19.6B
Cash Flow Margin N/A 19.7%
Net Cash / Leverage $11.95 Book/Sh · -34.5% ROE $27.7B Net Debt (0.55x D/E)
Dividend Yield None (0.00%) 1.94%
5. Options & Positioning JNJ
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 7.3% (30th %ile) 34.7% (45th %ile)
Put/Call OI Skew N/A 0.76x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat JNJ
OpEx & R&D Intensity N/A 41.2% of Rev ($40.9B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Pharmaceutical Preparations Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AKRO (3) vs JNJ (7)
Institutional Metric AKRO JNJ Criterion Row Edge
Market Capitalization
Scale
$4.5B $643.1B Larger Scale JNJ
Trailing P/E Ratio
Valuation
N/M 40.5x Lower Multiple JNJ
Forward P/E Ratio
Valuation
N/M 23.3x Lower Multiple JNJ
Revenue Growth (YoY)
Growth
+0.0% +5.9% Higher Growth JNJ
Operating Margin (TTM)
Profitability
0.0% 26.6% Higher Margin JNJ
Net Profit Margin
Profitability
0.0% 16.2% Higher Margin JNJ
Return on Equity (ROE)
Capital Efficiency
-34.5% 20.0% Higher ROE JNJ
52-Week Range Position
Momentum
90% ($21–$58) 78% ($199–$290) Stronger Trend AKRO
Beta / 30D Volatility
Risk Regime
0.90β · 2% Vol -0.04β · 25% Vol Lower Realized Risk AKRO
Unified Institutional Score
Composite Signal
60.0 / 100 (BUY) 57.8 / 100 (HOLD) Higher Composite AKRO
Trailing 12M Revenue (USD)
Operating Scale
N/A $99.3B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 67.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 3.07x PEG · 6.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($11.95 Book/Sh · -34.5% ROE) $19.6B ($27.7B Net Debt (0.55x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AKRO +1.01 pp
AKRO: +0.57% · JNJ: -0.44%
3M Horizon AKRO +1.01 pp
AKRO: +0.57% · JNJ: -0.44%
6M Horizon AKRO +1.01 pp
AKRO: +0.57% · JNJ: -0.44%
1Y Horizon AKRO +1.01 pp
AKRO: +0.57% · JNJ: -0.44%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKRO vs JNJ. Trailing 12-month operating profitability (AKRO 0.0% vs JNJ 26.6%) and valuation multiples (AKRO N/M vs JNJ 23.3x Forward P/E) are benchmarked directly in Pillar 4 below.

AKRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-34.5% · N/M
JNJ ADR TTM Benchmark FX-Normalized USD
TTM Revenue$99.3B
Gross Margin67.8%
Op. Margin26.6%
ROE / Fwd P/E20.0% · 23.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AKRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 7.3%
IV Percentile 30th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
JNJ CONSOLIDATION
66d in phase · OBV DISTRIBUTION
Current IV 34.7%
IV Percentile 45th %ile
Put/Call OI Skew 0.76x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact JNJ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $282.55 · IV 26.6%

JNJ Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($28,255)

Compare $28,255 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 26.6% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $280 / $300 Bull Call Spread

Buy 1x $280C · Sell 1x $300C · 31d

Net Entry $742 Debit
T+5d @ +5% Move +$526 (+71%)
Max Risk / Buffer $742 Capped
5d Edge & Liquidity 1.0x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $270 / $260 Bull Put Spread

Sell 1x $270P · Buy 1x $260P · 31d

Net Entry $240 Credit
Max Credit / Yield +$240 (+31.6% RoM)
Max Risk / Buffer -5.3% Cushion ($760 Mgn)
5d Edge & Liquidity 73% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 11 $265P / $285-$295C Seagull

Sell 1x $265P · Buy 1x $285/$295C · 24d

Net Entry $136 Debit
T+5d @ +5% Move +$486 (+11.4% RoM)
Max Risk / Buffer -6.2% Put Cushion ($4,261 Mgn)
5d Edge & Liquidity 0.7x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AKRO Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
JNJ Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $643.1B market capitalization and 26.6% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($40.9B)
90D Engineering Disclosures 0 Published

Investor FAQ AKRO vs JNJ Key Questions & Quantitative Answers

As of Nov 20, 2026, Johnson & Johnson (JNJ) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AKRO carries a Unified Composite Score of 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin), whereas JNJ carries 57.8/100 (HOLD) at $270.47 (23.3x Forward P/E, 26.6% operating margin). Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. JNJ 57.8/100 HOLD), JNJ captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (26.6% vs. 0.0% operating margin) and revenue trajectory (+5.9% vs. +0.0% YoY).

JNJ leads the Growth & Scale pillar: AKRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with JNJ at +5.9% YoY revenue growth and -95.9% YoY earnings growth on $99.3B TTM revenue (67.8% gross margin, 26.6% operating margin). On trailing 12-month operating scale, AKRO generates N/A in USD-normalized revenue versus $99.3B for JNJ. In operating R&D and SG&A reinvestment, AKRO deploys N/A (0 90-day corporate R&D disclosures) versus 41.2% of Rev ($40.9B) (0 disclosures) for JNJ.

JNJ screens cheaper on headline valuation multiples. AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas JNJ trades at 23.3x Forward P/E, 40.5x Trailing P/E, 3.07x PEG, and 6.8x EV/Revenue (19.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKRO (-34.5% ROE) versus JNJ (20.0% ROE) capital efficiency.

In options market volatility and institutional positioning, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk). By comparison, JNJ carries 34.7% implied volatility (45th %ile, Balanced (25th–60th %ile)), a 0.76x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.04β · 25% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.